Background. Plasmin is capable of degrading extracellular matrix components such as collagen in vitro. To evaluate the significance of this for in vivo conditions, we set out to study the effect of streptokinase, which acts by converting plasminogen to plasmin, on the serum concentrations of the amino-terminal propeptide of type III procollagen (PIIINP) and the carboxy-terminal propeptide of type I procollagen (PICP).
Background. Plasmin is capable of degrading extracellular matrix components such as collagen in vitro. To evaluate the significance of this for in vivo conditions, we set out to study the effect of streptokinase, which acts by converting plasminogen to plasmin, on the serum concentrations of the amino-terminal propeptide of type III procollagen (PIIINP) and the carboxy-terminal propeptide of type I procollagen (PICP).
Methods and Results. Twenty-three patients with suspected acute myocardial infarction were included in the study; 17 of them received thrombolytic therapy, and six were treated conservatively. PIIINP and PICP were assayed with radioimmunoassays. Kinetics of creatine kinase-MB release were determined to differentiate reperfusers from nonreperfusers. Composite curves of creatine kinase-MB release were constructed for different patient subgroups. During streptokinase infusion the serum concentrations of PIIINP increased rapidly, with a maximum mean increase of 50%o (from 2.2±0.2 to 3.3±0.3 ,ug/l) in 45 minutes. A similar increase was also observed in two patients who received thrombolytic therapy but did not subsequently develop any myocardial infarction determined on the basis of enzyme release. The relative increase in PIIINP during streptokinase treatment was higher in those acute myocardial infarction patients with probable reperfusion than those with nonprobable reperfusion. Corresponding changes in PIIINP were not seen in the control group. Two days later there was a second increase in serum PIIINP for both patient groups. This change coincided with a similar increase in PICP.
Conclusions. We conclude that streptokinase, probably by activation of plasminogen to plasmin, stimulates the breakdown of type III collagen during thrombolytic therapy. This phenomenon may decrease the risk of rethrombosis of the affected artery if the exposed collagen is responsible for thrombosis formation, but it could also be involved in the development of hemorrhagic complications during thrombolytic therapy. The The main collagens of the arterial wall are types I and III; the latter may be a more potent inducer of platelet aggregation17 and, when exposed to blood elements, may play a specific role in thrombosis formation and the development of acute myocardial infarction. Changes in the structure of vessel wall collagen have been suggested to be responsible for ruptures of arterial aneurysms in certain patients,'8 and the role of the subendothelial matrix in the pathophysiology of bleeding complications seen during thrombolytic therapy has been discussed. 19 We set out to determine whether the activation of plasminogen to plasmin also stimulates collagen breakdown in vivo. For this purpose ceived intravenous nitroglycerin and 250 mg of oral aspirin immediately on arrival. When patients were treated conservatively, one extra cannula was inserted into the cubital vein for repetitive blood sampling. The patients receiving streptokinase had two extra cannulas inserted, one for blood sampling and the other for streptokinase infusion. Streptokinase was always infused contralateral to the arm from which the blood samples were taken.
A total of 1.5 million U streptokinase was infused for 60 minutes into the patients in the thrombolytic treatment group. Any clinical signs of reperfusion (i.e., relief of chest pain, resolution of ischemic ST-T wave changes, and reperfusion arrhythmias) were noted.
The patients were treated in the coronary care unit until they had stabilized. All drugs, including ,-blockers, calcium channel blockers, nitrates, antiplatelet agents, heparin, and antiarrhythmics, were allowed because there are no previous reports of this kind of medication affecting collagen metabolism per se. The medication was adjusted daily according to the hemodynamic status, various infarct-related complications, and contraindications.
Coronary angiography was not performed routinely in the acute setting.
The blood-collecting schedule was the same for both groups of patients. Serum samples (10 ml of blood) for procollagen propeptide assays were taken before treatment at 15-minute intervals for the first hour and then at 1.5, 4, 8, 12, 18, 24, 48, 72 , and 96 hours in all and also at 120 hours in some patients. Creatine kinase (10 ml interval for adults, which is based on Finnish blood donors (n=88), is 1.7-4.2 ,g/l; there was no difference between women and men. 20 The concentration of PICP was assayed with a radioimmunoassay established recently in our laboratory.21 Type I procollagen was isolated from the medium of primary cultures of human skin fibroblasts; the protein was digested with bacterial collagenase, and PICP was purified by lectin-affinity chromatography, gel filtration, and ion-exchange separation on high-performance liquid chromatography. The final radioimmunoassay was established with polyclonal rabbit antibodies. This assay detects only one form of antigen in human serum with the same molecular size possessed by the isolated PICP. The intra-assay and interassay variations were about 3% and 5%, respectively. The sensitivity of the PICP assay, which was defined as the detectable mass equivalent to twice the mean±+SD of the zero binding value, was 1.2 ,ug/l. Serum PICP concentrations for those patients aged 18-61 ranged from 50 to 170 and 38 to 202 ,ug/l for healthy Finnish women and men, respectively.21 Statistical Analysis
For analysis of serial measurements, we basically used the principles of O'Brien and Shampo22 and Matthews et al. 23 Analysis of variance for repeated measurements was used to test the time-dependent differences in the concentrations of the procollagen propeptides. Because of the small number of patients in the two study groups, comparison between the treatments was done by determining the 95% confidence limits for the combined pretreatment values of procollagen propeptides in both patient groups and taking the subsequent values outside these limits to represent significant changes.
One-way analysis of variance followed by an unpaired t test was applied when the maximum changes in the PIIINP levels of various streptokinase-treated patient subgroups were compared with the changes seen in the conventionally treated patient group.
An unpaired t test was used when clinical characteristics between the two study groups were compared.
Results

Clinical Course of the Patients
The average time delay between the onset of symptoms and hospital admission was 8.9 hours for group I and 4.5 hours for group II (p<0.02). Clinical signs of reperfusion were encountered in 10 of the 17 patients receiving streptokinase but not in any of those treated conservatively (Table 1) .
All the patients survived and were stabilized during the 5-day period studied, and none needed immediate coronary angiography, angioplasty, or acute coronary bypass surgery.
Two patients receiving streptokinase had normal creatine kinase-MB levels throughout the treatment period, showing that no myocardial infarction occurred.
No serious bleeding or other complications were seen in the streptokinase group. Creatine Kinase Washout
Because angiography was not performed in the acute setting, the evaluation of reperfusion must necessarily rely on enzyme washout data. In terms of the creatine kinase-MB washout criteria of Shell et a124 and Gore et al,25 only five patients in the whole streptokinase group had a high probability of reperfusion during streptokinase treatment, despite 10 patients showing clinical signs of reperfusion ( Table  1 ). The rate of creatine kinase-MB release in the different subgroups of the acute myocardial infarction patients was evaluated by constructing composite curves for creatine kinase-MB activity, as was described earlier. 24 It is evident that the patients in the conservative treatment group and those in the streptokinase group, in whom reperfusion was unlikely, demonstrated similar patterns of creatine kinase-MB washout. Conversely, the release pattern was different in those patients who were reperfused during the streptokinase treatment ( Figure 1 ). Amino-Terninal Propeptide of Type III Procollagen PIIINP concentrations increased rapidly from 2.2±0.22 to 3.3 ±0.31 ,g/l during streptokinase infusion in which the highest concentration was observed after 45 minutes of the treatment. After that the concentrations decreased somewhat, although it remained above the level seen before treatment. There was no correlation between the PIIINP change and the maximum creatine kinase value attained (not shown). The PIIINP levels increased again after 2-3 days ( Figure 2A and Table 3 ).
There were two patients in the streptokinase treatment group who did not show creatine kinase-MB washout into blood and consequently did not develop myocardial infarction. Five of the 15 acute myocardial infarction patients in this group were considered to demonstrate probable reperfusion of the infarcted area, whereas 10 of them had a low probability for reperfusion (see above). All the subgroups receiving streptokinase developed significant increases in Pll-INP levels during the first hour of treatment compared with the conservatively treated patient group ( Table 2 ). The maximum increase of 1.4 ,ug/l in PIIINP was seen in the thrombolysis group with probable reperfusion. The percentage increases in the streptokinase group in which reperfusion was probable (89±27%) and the two patient groups of noninfarction with streptokinase treatment (90±3.5%) differed significantly from the percentage increase in the acute myocardial infarction group with nonprobable reperfusion (46±5.0%). However, when testing the absolute increases in the PIIINP concentrations between these subgroups, no significant differences were seen (Table 2) .
In group I (treated without thrombolysis) the PIIINP levels remained constant at 2.3-2.6 ,gg/l for the first 2 days, after which a later increase was observed that was similar to that seen in the streptokinase group ( Figure 2B ).
Carboxy-Terminal Propeptide of Type I Procollagen
The PICP levels stayed constant at the level of 58-64 and 85-90 ,g/l during the first few hours in the control and streptokinase treated groups, respectively. The time-dependent changes in PICP concentrations were similar in both groups. At 8-12 hours, a transient decrease of about 30% was observed. Increased levels of PICP were again noted after 2 days, coinciding with the later increase in PIIINP concentrations ( Figures 2C and 2D) .
Fibrinogen Degradation Products
There was a rapid increase of FDP after streptokinase treatment, and the levels stayed high for 2-3 days from the start of the treatment. In the control group, FDP stayed normal throughout the observation period. The streptokinase-induced increase was much higher in FDP than PIIINP (Table 3) .
Discussion
The interstitial collagens are synthesized and secreted as larger precursor molecules called procollagens. These molecules contain additional collagen type-specific propeptide sequences at both the N and C-terminal ends. The propeptides are cleaved off from the collagen molecules before they assemble to form fibers. Thus, the amount of the free propeptide stoichiometrically should reflect the amount of collagen molecules deposited. This idea seems to hold for the C-terminal propeptides of interstitial collagens. However, the N-terminal propeptide of collagen type III is not completely cleaved, and many molecules retain the propeptide while already in the fibers. Such molecules are located on the surface of the fibers and seem to limit further growth of the fibril diameter. These molecules are presumably also degraded first when the fiber is dissolved. Thus, the amount of free PIIINP is not directly related to the synthesis rate of type III collagen because some of the soluble antigens may be derived from degradation of type III collagens of the fibers.13, 15 We hypothesized that streptokinase itself, or more probably plasmin, known to act as unspecific proteinase and also to possess collagenase activating properties,5-10 could be able to degrade surface molecules of interstitial type III collagen, and thus lead to very rapid changes in PIIINP blood levels. To exclude rapid changes in collagen synthesis or disposal rates, PICP (a pure synthesis marker13) was assayed as a control. PIIINP and PICP radioimmunoassays resemble each other,2021 and if unspecific factors are involved they should affect both assays similarly.
Because the PICP levels did not increase here during streptokinase treatment, it is highly improbable that the very rapid increase in PIIINP concentrations could be caused by increased synthesis, reduced elimination of the antigen from the blood stream, or any other unspecific factors disturbing the radioim- attained less than 11 hours after commencement of streptokinase treatment, which suggests reperfusion. By means of both of these creatine kinase washout criteria, reperfusion of the infarct-related coronary artery was probably achieved in five of the 15 acute myocardial infarction patients treated here with streptokinase (Tables 1 and 2 ). The maximum percentage increase of PIIINP during streptokinase infusion in these five patients was higher than in the rest of the streptokinase-treated AMI patients (Table 2). However, there were no statistically significant differences in the absolute changes in the concentrations. Therefore, no conclusions can be drawn on the contribution of the heart muscle to serum PIIINP during streptokinase infusion. Studies with more selective blood sampling from the coronary sinus during streptokinase treatment are probably needed to settle this problem. It is noteworthy that although increased during streptokinase treatment, serum levels of PIIINP remained normal throughout the observation period. However, this finding does not exclude significant local collagen degradation because considerable dilution in the circulating propeptide concentration may occur if only one or two organs are involved.
Bleeding is a major complication of treatment with thrombolytic agents. Because of their milder effects on the coagulation mechanism, fibrin-selective agents were expected to have a lower incidence of bleeding complications. However, in controlled trials the incidence of bleeding complications has little correlation with the extent of the fibrinogenolysis produced by a particular thrombolytic agent, 28 and it has been suggested that vascular injury is the main cause of bleeding rather than the changes in the coagulation state. 19 The relative changes in FDP 
